Annual Report FY2025-26 and Notice of 32nd AGM on Sept 29, 2026

Board & Shareholder Meetings View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

—Next day

₹133.75

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%—

Pharmaceuticals peers, median of 177sector-0.3%—

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—+0.5—+0.2—

Next day

—+0.4—-0.3—

—+0.2—+0.0—

—+0.3—-0.5—

+1.0-3.0+4.0-2.0+3.0

—-3.1—-2.0—

—-0.7—-0.9—

15d

—-1.2—-1.9—

—-4.2—-4.4—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 177Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Parmax Pharma filed its Annual Report for FY2025-26 (year ended March 31, 2026) along with notice of its 32nd AGM to be held on September 29, 2026 at 3:30 PM via video conferencing. Remote e-voting runs from September 26 to 28, 2026 with cut-off date September 22, 2026. AGM items include adoption of financial statements, re-appointment of Managing Director Umang Gosalia, appointment of Dhiren Shah as Non-Executive Chairman, Sunil Shah as Non-Executive Director, and two independent directors for 5-year terms.

Likely market impact

Shareholders can review the annual report and vote on resolutions including director appointments at the upcoming virtual AGM.